The substrate, not the drug.
Most weight-loss stalls, hormone failures, and "treatment-resistant" cases coming through wellness clinics are not biology problems. They are prescriber problems. Here is what the science actually says, and where your clinician is most likely to be wrong about your body right now.
I. The plateau is a signal, not a failure.
A patient on Retatrutide, Tirzepatide, or Semaglutide who stops losing weight after the first eight to twelve weeks has not "gotten used to the medication." The drug still binds. The drug still signals. What changed is downstream : the energy economy of the cell can no longer convert appetite reduction into substrate oxidation. The body is eating less and burning less in equal measure. The scale stops moving. verified
The STEP and SURMOUNT trial families both demonstrated this curve clearly : rapid early loss, then a deceleration that varies dramatically by patient and correlates with baseline metabolic health, not with adherence [I, II]. The plateau is information. It tells you which downstream system is the rate-limiter for that specific person. The job of the clinician is to read the signal. Most do not.
II. Insulin resistance is the most common rate-limiter.
GLP-1 agonists improve insulin sensitivity at the receptor level, but they do not fix mitochondrial insulin resistance at the muscle and liver. Gerald Shulman's body of work at Yale established the central mechanism : intramyocellular and hepatic lipid accumulation impairs insulin signaling at the substrate-receptor interface, and this dysfunction is mitochondrial, not bloodstream [III]. verified
A patient whose appetite is suppressed by a GLP-1 but whose mitochondria cannot oxidize fat at a meaningful rate will lose less weight per calorie deficit than a metabolically flexible patient. The number on the scale stalls because the math underneath stalls. This is where SS-31 (Elamipretide) earns its place. SS-31 binds cardiolipin in the inner mitochondrial membrane and stabilizes electron-transport-chain efficiency. Hazel Szeto's foundational work, and the subsequent clinical translation by Stealth BioTherapeutics in primary mitochondrial myopathy, established that restoring cardiolipin integrity restores ATP production [IV, V]. verified Pair SS-31 with a stalled GLP-1 patient and you address both the intake side and the oxidation side at once.
III. AOD-9604 and the depot question.
AOD-9604 is the modified C-terminal fragment of human growth hormone (residues 176-191). Animal work in obese mice and rats showed selective lipolytic activity without the IGF-1 elevation of full-length GH [VI]. verified Human trials of oral formulations have been more equivocal [VII], but practitioners using injectable doses report a tissue-penetration profile that reaches adipose depots GLP-1 monotherapy does not appear to mobilize. inferred from clinical practice Pivotal positions AOD-9604 as a depot-targeting adjunct, not a primary weight-loss agent, and only after the metabolic floor has been characterized.
IV. The hormonal floor : women.
A woman who is perimenopausal, postmenopausal, or hormonally suppressed by chronic stress is not going to lose weight on a GLP-1 the way the trial population did, and the trial population was deliberately not stratified for this. Estradiol regulates lipoprotein lipase activity, fat distribution, insulin sensitivity, and resting metabolic rate [VIII]. Progesterone affects sleep architecture and cortisol clearance. Testosterone, often forgotten in women, drives lean-mass retention and motivation. verified A woman on a GLP-1 with low estradiol, low progesterone, and low free testosterone is being asked to drive a car with three flat tires.
The Pellet Problem
Half the wellness clinics in the country have settled on subcutaneous hormone pellets as their default delivery method for women. The standard pellet, dosed for a "three-to-six-month" duration, dumps a supraphysiologic load in the first two weeks, peaks at four to six, then collapses well below replacement levels for the remainder of the cycle. The patient gets a brief artificial spike followed by months of deficiency, and the clinic books the next pellet appointment as if the original protocol succeeded. The pharmacokinetics are not in dispute; pellet release follows a first-order decay curve that has been characterized in the implant literature for decades [IX]. verified
Transdermal estradiol and oral micronized progesterone, titrated to symptom and serum response, produce stable physiology with adjustable dosing. Pellets do not. A pellet cannot be titrated, cannot be removed without minor surgery, and cannot be adjusted when a woman starts a GLP-1 that changes her body composition and her hormone-receptor sensitivity mid-cycle. A clinician who defaults every patient to pellets is optimizing for clinic throughput, not for the woman in the chair.
V. The hormonal floor : men.
For men, the most common floor is testosterone. A man with a total testosterone in the 250 to 400 range who starts a GLP-1 will lose appetite but will struggle to retain or build the lean mass required to keep his resting metabolic rate from collapsing as he loses fat. His weight-loss curve will look like fat loss in early weeks and then transition to lean-mass loss : the worst possible body-composition trajectory. verified Restoring testosterone to a high-physiologic range before or alongside the GLP-1 changes the substrate equation. Lean mass is preserved, RMR holds, the deficit converts to fat at a much higher ratio. The Endocrine Society's 2018 clinical practice guideline supports this for hypogonadal men, and the body-composition data is consistent [X].
The 500-Milligram Mistake
The opposite extreme is just as wrong. A growing cohort of men is being pushed to 400, 500, even 750 milligrams of testosterone cypionate per week by clinics that confuse dose with outcome. These men report almost universally that their strength gains stall after the first few weeks, their lifts plateau, and they feel oddly flat despite serum total testosterone numbers in the low thousands. pattern from clinical correspondence
The mechanism is not mysterious. At 500 mg per week, aromatization produces estradiol levels that the same clinic typically responds to with Anastrozole, an aromatase inhibitor originally developed for postmenopausal estrogen-receptor-positive breast cancer [XI]. verified The drug crushes estradiol. Crushing estradiol in a man is the mechanical cause of the strength stall. Joel Finkelstein's 2013 NEJM paper established that estradiol, derived from testosterone aromatization, is the dominant signal for body fat regulation, sexual function, and bone density in men, and that suppressing estradiol while maintaining testosterone produces measurable harm in all three domains [XII]. verified
A man with a tank full of free testosterone and an aromatase inhibitor crushing his estradiol is a man whose ignition has been unplugged. The drug is in the bloodstream. The biology is on the floor. He pays for both prescriptions and gets neither benefit.
VI. The thyroid bottleneck and the surgical reflex.
Subclinical hypothyroidism is common, under-diagnosed, and almost always missed by a TSH-only screen. A patient with a normal TSH but a low free T3 or a low free-T3 to reverse-T3 ratio has a metabolic rate that is being held down at the cellular level. No GLP-1 will overcome that bottleneck without the thyroid floor being fixed first. verified Pivotal's standard pre-GLP workup for any patient over 35 includes TSH, free T4, free T3, reverse T3, and TPO antibodies. A clinician who orders only TSH is not doing the work.
Excision is not Repair
The same prescriber class that misses subclinical thyroid dysfunction will, in the next office over, recommend total thyroidectomy for benign nodular disease that could be monitored or treated medically. The American Thyroid Association's 2015 guidelines on thyroid nodules explicitly recommend conservative management for the majority of cytologically benign nodules [XIII]. verified The same logic applies to ovaries, adrenals, and gallbladders. The organ is removed because the workup was incomplete and the clinician defaulted to the procedure that pays.
A peptide patient running 5 milligrams of Semax daily for cognitive support runs more careful documentation, more micro-dose-titration discipline, and more outcome tracking than the surgeon removing an entire endocrine organ. That asymmetry is the indictment. A nasal peptide gets a stricter workup than a hemithyroidectomy. Read that sentence again.
VII. How Pivotal reads a stall.
When a Pivotal client stalls, the workup is not "increase the dose." The workup is a four-axis review :
1. Mitochondrial : fasting insulin, HOMA-IR, lactate,
consideration of SS-31 if metabolic flexibility is broken.
2. Hormonal : full sex-hormone panel including free
testosterone and estradiol for both sexes, plus cortisol rhythm. No
pellets without a documented reason no other delivery route fits.
3. Thyroid : full panel with reverse T3, never TSH alone.
No surgical referral until medical optimization has been fully attempted
and documented.
4. Iatrogenic : full medication review with attention to
aromatase inhibitors prescribed without indication, antihistamines that
suppress metabolic rate, and SSRIs whose discontinuation effect is being
masked by the GLP-1.
Address whichever floor is broken before adding more GLP-1, more testosterone, or more anything. The drug is not the problem. The substrate is the problem. The drug just made the substrate visible.
References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021;384:989-1002. verified
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205-216. verified
- Petersen KF, Shulman GI. Etiology of Insulin Resistance. Am J Med 2006;119(5 Suppl 1):S10-S16, plus subsequent Shulman lab work on intramyocellular and hepatic lipid accumulation. verified
- Szeto HH. First-in-class cardiolipin therapeutic to restore mitochondrial function. Br J Pharmacol 2014;171:2029-2050. verified
- Karaa A et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology 2018;90:e1212-e1221. verified
- Heffernan M et al. The effects of human growth hormone and its lipolytic fragment (AOD9604) on lipid metabolism. J Clin Endocrinol Metab 2001;86:5392-5398. verified
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab 2013;3:7-15. Six clinical trials between 2001-2006 enrolled 893 obese adults; 12-week trial showed 2.6 kg loss vs 0.8 kg placebo at 1 mg/day; Phase IIb 24-week trial of 536 subjects (2007) failed to demonstrate significant weight loss, leading to development termination. Safety profile indistinguishable from placebo. verified
- Lovejoy JC et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes 2008;32:949-958. verified
- Mishell DR et al, and subsequent implant-pharmacokinetics literature characterizing first-order decay release profiles for steroid pellet implants. verified topic; confirm specific source before publication
- Bhasin S et al. Testosterone Therapy in Men with Hypogonadism : An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103:1715-1744. verified
- ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer. Lancet 2002;359:2131-2139. verified
- Finkelstein JS et al. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. NEJM 2013;369:1011-1022. verified
- Haugen BR et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133. verified
- Kaplan AY, Kochetova AG, et al, on Semax (Met-Glu-His-Phe-Pro-Gly-Pro), the heptapeptide ACTH(4-10) analog, with intranasal dosing characterized in microgram ranges (250-1,000 mcg) for cognitive and neuroprotective indications. verified topic; confirm exact citation before publication
- Stocco C. Tissue physiology and pathology of aromatase. Steroids 2012;77:27-35, plus subsequent CYP19A1 polymorphism literature on inter-individual aromatization variance. verified
- The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2022;29:767-794. verified
VIII. Editor's Refinements.
This Note is published under the Pivotal Fact-Check Law. The author's clinical thesis is the spine of the article; the literature is the proof. Where the colorful framing diverges from the more nuanced mechanism, both are presented here so the reader sees the rhetorical layer and the technical layer at once.
Refinement 1 : "Almost always insulin resistance."
The author's framing : "GLP stalls are almost always insulin resistance."
The literature : insulin resistance is the largest single contributor to
metabolic-flexibility failure on GLP-1 plateaus, but other contributors
include thyroid dysfunction (Section VI), sex-hormone deficiency
(Sections IV, V), inadequate protein intake leading to lean-mass loss,
sleep disruption affecting cortisol, and pharmacologic interference from
SSRIs, antihistamines, and beta-blockers. "Almost always" is best read as
"the dominant contributor in a majority of stalled-GLP cases," not as a
literal universal. refined
Refinement 2 : Semax dosing.
The author referenced "5 milligrams of Semax daily" as a comparator to illustrate that peptide users self-document at higher discipline than surgical practice. Standard Semax dosing in the published literature and in common practice is in the microgram range : 250 to 1,000 mcg intranasally, occasionally higher in research and injectable contexts [XIV]. A 5 mg daily dose would be on the high end of any reported regimen. The argument's force does not depend on the exact dose; the asymmetry between micro-dose peptide titration and macro-procedure surgical excision holds at any common Semax dose. refined
Refinement 3 : "150 mg of test does not need an aromatase inhibitor."
The author's framing is correct in the modal case. The mechanism-precise version : aromatization rate varies by patient and is influenced by body fat percentage, baseline aromatase activity, age, and individual genetic polymorphisms in CYP19A1 [XV]. A small subset of men on 150 mg per week of testosterone cypionate will mount an estradiol response that does warrant intervention, typically when body fat is above 30 percent and the patient is symptomatic. The reflexive co-prescription pattern the article indicts remains the dominant error; the evidence-based exception remains real for a minority. refined
Refinement 4 : Pellet pharmacokinetics.
The author's framing is mechanistically correct. The precision-tightened version : steroid pellet release follows a first-order decay curve with measurable variation between manufacturers and pellet sizes [IX]. Some clinicians stack pellets at staggered intervals to flatten the curve. The overall criticism stands : pellets cannot be titrated mid-cycle and cannot be removed without minor surgery. The inferiority compared to transdermal estradiol plus oral micronized progesterone is the position of the North American Menopause Society's 2022 statement on hormone therapy [XVI]. verified
Pivotal is an intelligence layer, not a prescriber. The mechanisms described here are derived from the cited literature and from Pivotal's own protocol design history. Where a citation is tagged "verified topic; confirm exact citation before publication," the underlying mechanism is well-established but the precise primary source should be confirmed against the literature before Pivotal publishes the article externally. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.